 | | Vol. 13.06 – 15 February, 2022 |
| |
|
|
| Scientists demonstrated that yeast-derived particulate β-glucan, an inducer of trained immunity, trafficked to the pancreas, which caused a CCR2-dependent influx of monocytes/macrophages to the pancreas that displayed features of trained immunity.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Using global stimulator of interferon genes (STING) knockout (STING−/−) and β-cell–specific STING knockout mouse models, scientists revealed a distinct role of STING in the regulation of glucose homeostasis through peripheral tissues and β-cells.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Using four conditional cell lineage tracing murine models, researchers described the natural history of pancreatic islet cells, from once they express a hormone gene, until late in life.
[Cell Reports] |
|
|
|
| Investigators showed that Mycl played a key role in proliferation of pancreatic endocrine cells. In vitro expression of Mycl provoked active replication in islet cells, even in those from aged mice.
[Nature Metabolism] |
| |
|
|
| Tumor-associated macrophages are abundant, and they are important mediators of disease progression and invasion. Scientists generated tumor-educated macrophages in vitro and performed detailed, multiomic characterization.
[eLife] |
|
|
|
| Researchers identified normal epithelial cells in the tumor lesion of PDAC patients, which had euploid genomes, normal patterns of DNA methylation, and chromatin accessibility.
[Cell Discovery] |
|
|
|
| Panc-1 and MiaPaCa-2 cells treated chronically with gemcitabine displayed increased transcription and expression of cancer stem cell-associated markers.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Researchers proposed to construct an immune-related prognostic risk model based on immune-related genes MMP14 and INHBA expression that could assess the prognosis of pancreatic cancer patients and identify potential therapeutic targets for pancreatic cancer.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| The authors examined differences in N-glycans, O-glycans, and glycosphingolipid glycans in PaTu-8955S (PaTu-S) cells upon TGF-β stimulation.
[Journal of Biological Chemistry] |
|
|
|
| Scientists developed two quantifications methods to explore BRCA1 and RAD51C promoter methylation in a series of 121 Formalin Fixed-Paraffin-Embedded specimens from resected pancreatic adenocarcinoma without neoadjuvant treatment.
[Clinics and Research in Hepatology and Gastroenterology] |
|  |
|
|
|
| The authors highlight potential adverse effects of accumulative combination, and further points out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving precision of treatment.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
|
| Zealand Pharma A/S announced completion of patient enrollment in the second Phase III-trial, 17103, of dasiglucagon for the treatment of CHI in neonates up to 12 months old.
[Zealand Pharma, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| March 20 – March 25
Vienna, Austria |
|
|
|
|
|
| Karolinska Institute – Stockholm, Sweden |
|
|
|
| University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | University of Texas Medical Branch – Galveston, Texas, United States |
|
|
|
| | Knight Cancer Institute – Portland, Oregon, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
